Nob Hill Therapeutics, an early-stage pulmonary medical device and therapeutics company, today announced the first close of a $3 million Series A financing round. The round was led by new investor Tramway Venture Partners and included investments from TCA Venture Group and VIC Technology Venture Development (which founded NHT). In connection with the financing, Chris Japp, Managing Partner of Tramway Venture Partners, will join Nob Hill's Board of Directors. Sima Ghafari of TCA Venture Group will join as a Board Observer.

Nob Hill Therapeutics (NHT) is a respiratory-focused healthcare company that uses high dose lung delivery to change the treatment paradigm for lung-related diseases. NHT's patented Dry Powder Nebulizer platform has several technological innovations that enable it to generate highly efficient drug aerosols and deliver them effectively to the lower respiratory tract, independent of the patient's lung capacity.